PANCREAZE
LOE Approachingpancrelipase lipase, pancrelipase amylase, and pancrelipase protease
BLAORALCAPSULE, DELAYED RELEASE
Approved
Apr 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
PANCREAZE (pancrelipase lipase, pancrelipase amylase, and pancrelipase protease) is lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas. Approved for exocrine pancreatic insufficiency in adult. First approved in 2010.
Drug data last refreshed 12h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PANCREAZE is an oral delayed-release capsule containing pancrelipase enzymes (lipase, amylase, and protease) that replace missing digestive enzymes in patients with exocrine pancreatic insufficiency. It works by catalyzing the hydrolysis of fats, proteins, and starches in the small intestine, mimicking the natural digestive function of a healthy pancreas.
$10MPart D
LOE ApproachingApproaching loss of exclusivity signals declining team resources and shifting focus toward retention and generic transition strategies.
Mechanism of Action
lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting…
Indications (1)
Clinical Trials (1)
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
Started Dec 2020
36 enrolled
Pancreatic Adenocarcinoma
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.